“This research highlights the potential of GMMA technology to support a new generation of affordable, needle-free vaccines,” said Dr. Fatme Mawas, Head of Conjugate Vaccines at the Medicines and Healthcare products Regulatory Agency (MHRA).
A potential vaccine against the group A streptococcus bacterium has advanced following preclinical research conducted by the MHRA in partnership with the GSK Vaccines Institute for Global Health. The study was published in October 2026 in the journal Human Vaccines & Immunotherapeutics.
Strep A causes more than 600 million infections worldwide each year, leading to over 500,000 deaths annually from associated complications. While most cases remain mild, severe outcomes include scarlet fever, rheumatic heart disease, and invasive infections that can cause long-term disability or death, particularly in low- and middle-income regions.
There is currently no licensed vaccine available to prevent Strep A infections globally.
The experimental vaccine utilizes generalized modules for membrane antigens, known as GMMA. These components consist of tiny bubbles naturally shed by bacteria, functioning simultaneously as a carrier for Strep A carbohydrates and as an adjuvant to stimulate the immune system.
Unlike conventional vaccine designs that concentrate primarily on generating antibodies within the bloodstream, this platform targets mucosal surfaces in the nose and throat. This is the exact site where Strep A typically establishes an infection.
“By delivering a Strep A vaccine through the nose or under the tongue, we showed that strong immune responses were generated both at the mucosal surfaces where infection begins and throughout the body, supporting protection against invasive disease,” Mawas said.
The pre-clinical evaluation relied on a mouse model to test the efficacy of administering the glycoconjugate vaccine either intranasally or sublingually. Researchers James Ozanne, Manolya Saydam, Elena Palmieri, and their colleagues authored the study, titled “GMMA as adjuvant and carrier for mucosal delivery of group A streptococcus glycoconjugate vaccine.”
Public health authorities emphasize that needle-free administration could simplify logistics and distribution in regions with high disease burdens. The technology aims to reduce reliance on trained personnel required for traditional injections.
“This approach could make vaccines easier to administer and more accessible globally, particularly in low- and middle-income countries where the burden of Strep A disease is greatest,” Mawas said.
Preventing primary infections before they occur also reduces the need for antibiotics. Researchers note that lower antibiotic consumption supports broader international initiatives to combat antimicrobial resistance.
Developing a safe and effective vaccine has proved challenging due to the bacterium’s ability to evade human immune responses and the risk of triggering autoimmune complications, such as rheumatic heart disease.
GMMA are natural membrane bubbles shed by bacteria that carry targeted carbohydrates while boosting the body’s immune reaction without requiring separate chemical adjuvants.
The Medicines and Healthcare products Regulatory Agency (MHRA), established in 2003 through the merger of the Medicines Control Agency and the Medical Devices Agency, operates as an executive agency of the Department of Health and Social Care. Beyond its regulatory mandate, the agency conducts scientific research to enable innovation, including the conjugate vaccine work led by Dr. Fatme Mawas.
In December 2020, the MHRA became the first medicines regulator in the world to grant temporary authorisation for the Pfizer–BioNTech COVID-19 vaccine. In 2023, it was the first regulatory authority globally to approve Casgevy, a CRISPR-based gene-editing therapy for sickle cell disease and transfusion-dependent beta thalassaemia.
Following successful pre-clinical testing in mouse models published on October 19, 2026, the findings support further development toward human clinical trials.
Worth a look